|135.99||+0.6500||+0.48%||Vol 571.15K||1Y Perf 115.77%|
|Sep 15th, 2021 16:00 DELAYED|
|- -%||- -|
|Target Price||132.40||Analyst Rating||Strong Buy 1.25|
|Potential %||-2.64||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/100/-53||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-/100/-53||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/100/-53||Income Ranking||— -|
|Price Range Ratio 52W %||95.71||Earnings Rating||Strong Buy|
|Market Cap||8.89B||Earnings Date||8th Nov 2021|
Today's Price Range
|Moving Averages:||Strong Buy|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||8th Nov 2021|
|Estimated EPS Next Report||-2.65|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||355.54K|
|Avg. Monthly Volume||343.72K|
|Avg. Quarterly Volume||615.02K|
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) stock closed at 135.99 per share at the end of the most recent trading day (a 0.48% change compared to the prior day closing price) with a volume of 573.41K shares and market capitalization of 8.89B. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 647 people. Biohaven Pharmaceutical Holding Company Ltd. CEO is Vlad Coric.
The one-year performance of Biohaven Pharmaceutical Holding Company Ltd. stock is 115.77%, while year-to-date (YTD) performance is 58.66%. BHVN stock has a five-year performance of %. Its 52-week range is between 57.7 and 139.5, which gives BHVN stock a 52-week price range ratio of 95.71%
Biohaven Pharmaceutical Holding Company Ltd. currently has a PE ratio of -9.30, a price-to-book (PB) ratio of 29.80, a price-to-sale (PS) ratio of 45.61, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -137.37%, a ROC of -751.37% and a ROE of 361.70%. The company’s profit margin is -%, its EBITDA margin is -391.90%, and its revenue ttm is $189.53 Million , which makes it $2.90 revenue per share.
Of the last four earnings reports from Biohaven Pharmaceutical Holding Company Ltd., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-2.65 for the next earnings report. Biohaven Pharmaceutical Holding Company Ltd.’s next earnings report date is 08th Nov 2021.
The consensus rating of Wall Street analysts for Biohaven Pharmaceutical Holding Company Ltd. is Strong Buy (1.25), with a target price of $132.4, which is -2.64% compared to the current price. The earnings rating for Biohaven Pharmaceutical Holding Company Ltd. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Biohaven Pharmaceutical Holding Company Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Biohaven Pharmaceutical Holding Company Ltd. has a Buy technical analysis rating based on Technical Indicators (ADX : 5.97, ATR14 : 4.90, CCI20 : 76.35, Chaikin Money Flow : -0.02, MACD : 4.04, Money Flow Index : 71.44, ROC : 4.46, RSI : 61.41, STOCH (14,3) : 75.96, STOCH RSI : 1.00, UO : 37.53, Williams %R : -24.04), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Biohaven Pharmaceutical Holding Company Ltd. in the last 12-months were: Charles Conway (Option Excercise at a value of $0), Elyse Stock (Option Excercise at a value of $0), Gregory Hugh Bailey (Sold 50 000 shares of value $3 959 252 ), James Engelhart (Option Excercise at a value of $0), John Tilton (Option Excercise at a value of $0), John W. Childs (Buy at a value of $2 495 867), Kimberly Gentile (Option Excercise at a value of $218 315), Kimberly Gentile (Sold 23 500 shares of value $1 794 082 ), Vlad Coric (Option Excercise at a value of $0), William B.J. Jones (Option Excercise at a value of $1 521 600), William B.J. Jones (Sold 30 000 shares of value $2 286 676 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.